Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients

Neurology

Volumn 50, Issue 5, 1998, Pages 1327-1331

  Growdon, J H ^a   Kieburtz, K ^d   McDermott, M P ^d   Panisset, M ^b   Friedman, J H ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^d WAC 830 ^*

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; COGNITION; DEPRESSION; DISABILITY; DREAM; FEMALE; FRONTAL LOBE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE;

EID: 0031816175     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1327     Document Type: Article

References (29)

1. Beardsley JV, Puletti F. Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment: occurrence in patients with Parkinson's disease. Arch Neurol 1971;25:145-150.
2. Loranger AW, Goodell H, Lee JE. Levodopa treatment of Parkinson's syndrome: improved intellectual functioning. Arch Gen Psychiatry 1972;26:163-168.
3. Huber SJ, Shulman JG, Paulson GW, Shuttleworth EC. Dose-dependent memory impairment in Parkinson's disease. Neurology 1989;39:438-440.
4. Poewe W, Berger W, Benke T, Schelosky L. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991;29:670-673.
5. Prasher D, Findley L. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation. J Neurol Neurosurg Psychiatry 1991;54:603-609.
6. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984;ii:1262-1265.
7. Mayeux R, Stern Y, Rosenstein R, et al. An estimate of he prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988;45:260-262.
8. Growdon JH, Corkin S, Rosen TJ. Distinctive aspects of cognitive dysfunction in Parkinson's disease. In: Streifler MD, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in neurology: Parkinson's disease: anatomy, pathology, and therapy. New York: Raven Press, 1990;53:365-376.
9. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;49:283-293.
10. Cummings JL. Depression and Parkinson's disease a review. Am J Psychiatry 1992;149:443-454.
11. Miyoshi K, Ueki A, Nagano O. Management of psychiatric symptoms of Parkinson's disease. Eur Neurol 1996;36(suppl 1):49-58.
12. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135: 669-675.
13. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-1920.
14. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996; 53:1265-1268.
15. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46:1052-1060.
16. Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology 1994;44:1756-1759.
17. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte J, Agid Y. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989;52:201-206.
18. Cooper JA, Sagar HJ, Sullivan EV. Short-term memory and temporal ordering in early Parkinson's disease: effects of disease chronicity and medication. Neuropsychologia 1993;31: 933-949.
19. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992; 115:1701-1725.
20. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain 1986;109:845-883.
21. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992;107:394-404.
22. Lange KW, Paul GM, Naumann M, Gsell W. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neurol Transm 1995;46:423-432.
23. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988;111:299-321.
24. Kulisevsky J, Avila A, Barbano M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119: 2121-2132.
25. Malapani C, Pillon B, Dubois B, Agid Y. Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunction. Neurology 1994;44:319-326.
26. Pullman SL, Watts RL, Juncos JL, Chase TN, Sanes JN. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 1988;38:249-254.
27. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65: 115-138.
28. Banerjee AK, Falkai PG, Savidge M. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J 1989;65:358-361.
29. Girotti F, Carella F, Grassi MP, Soliveri P, Marano R, Caraceni T. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry 1986;49:657-660.